Utah Medical Products, Inc. Announces Quarterly Dividend

SALT LAKE CITY, UT / ACCESS Newswire / February 4, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty-one cents ($.31) per share of common stock payable on April 3, 2026 to stockholders of record at the close of business on March 17, 2026. This is a 1.6% increase over the dividend declared in the same quarter of the prior year.

Accesswire • Feb 4, 2026

Utah Medical's Q4 Earnings Hurt by OEM Decline, Fall Y/Y

UTMD's Q4 earnings fall year over year due to weak OEM sales and lower international Filshie sales, but strong U.S. Filshie growth and steady margins help offset broader revenue pressure.

Zacks Investment Research • Feb 4, 2026

Utah Medical Products, Inc. Appoints Director and Increases Quarterly Dividend

SALT LAKE CITY, UT / ACCESS Newswire / November 4, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors has appointed Kevin C. Timken, Esq to its Board of Directors.

Accesswire • Nov 4, 2025

UTMD's Q3 Earnings Dip Y/Y on Trade Disruptions, Margins Squeeze

Utah Medical's Q3 earnings fell 20% year over year as order cancellations and tariffs pressured margins. Growth in U.S. Filshie devices and direct sales helped partially offset declines.

Zacks Investment Research • Oct 29, 2025

UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2025

SALT LAKE CITY, UT / ACCESS Newswire / October 23, 2025 / Utah Medical Products, Inc. (NASDAQ:UTMD) reports third quarter (3Q) and first nine months (9M) of calendar year 2025 financial results that were unusually hampered by global trade uncertainty. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.

Accesswire • Oct 23, 2025

UTMD's Q2 Earnings Slip Y/Y Due to Falling OEM Sales, Stock Down 3%

Utah Medical's Q2 earnings decrease year over year on lower OEM sales and weak international demand, though cost controls helped cushion margins.

Zacks Investment Research • Jul 30, 2025

Utah Medical Products Reports Q2 Decline

Utah Medical Products Reports Q2 Decline

The Motley Fool • Jul 25, 2025

UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2025

SALT LAKE CITY, UT / ACCESS Newswire / July 24, 2025 / Utah Medical Products, Inc. [Nasdaq:UTMD] reports second calendar quarter (2Q) and first half (1H) 2025 financial results which are consistent with overall beginning-of-year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.

Accesswire • Jul 24, 2025

Utah Medical Products: Deep Discount Is Drawing One Legendary Investor's Interest

I reiterate my strong buy on UTMD, citing its robust balance sheet, disciplined capital allocation, and 43% upside to my $82.22 price target. Revenue headwinds appear to be stabilizing, with legendary value investor Charles Brandes taking a 7.4% stake, signaling renewed institutional interest. Key risks include Filshie Clip litigation, declining China sales, and succession planning, but UTMD's undervaluation and cash reserves limit downside.

Seeking Alpha • Jul 3, 2025

Stock Picks From Seeking Alpha's April 2025 New Analysts

In April, Seeking Alpha welcomed 20 new analysts. This article introduces them and showcases some of their top picks. Top picks include Palantir, Arch Capital Group, and Utah Medical Products, emphasizing an under-recognized growth driver, discounted valuation, and a substantial margin of safety. Analysts also highlighted Sell recommendations on Estée Lauder and Intuitive Surgical, citing deteriorating consumer sentiment and little price upside.

Seeking Alpha • May 6, 2025